FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza
FDA Approves Xofluza (baloxavir marboxil) for the Treatment of Acute Uncomplicated Influenza Print this page October 24, 2018 — Today, the U.S. Food and Drug Administration approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48… Read More »